Human monoclonal anti-idiotypic antibodies as an epitope vaccine against pancreatic carcinoma.
During therapeutic repetitive application of MAb BW 494 in pancreatic carcinoma patients, a human IgG anti MAb BW 494 response arose, which was analyzed on the B cell clonal level as well as in the serum of these patients 2-4 months after treatment. From 5 investigated patients 3 developed a polyclonal human IgG anti-idiotypic response in the serum and had B cells with the same specificity which could be immortalized by EBV transformation. Two out of 5 patients showed an anti-idiotypic and anti-isotypic polyclonal response which could be found on the B cell clonal level as well. The data indicated that the human IgG anti MAb BW 494 response was mainly anti-idiotypic.
Bosslet
K
K
Research Laboratories of Behringwerke AG, Marburg/Lahn, W. Germany.
Büchler
M
M
Klapdor
R
R
Muhrer
C
C
Sedlacek
H H
HH
Schulz
G
G
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000032:analysis; D000941:Antigens / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D007130:Immunoglobulin Idiotypes / Q000276:immunology*; D010190:Pancreatic Neoplasms / Q000276:immunology / Q000628:therapy*; D014614:Vaccines, Synthetic / Q000276:immunology / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000941:Antigens; D000951:Antigens, Neoplasm; C042317:DU-PAN-2 antigen, human; D007074:Immunoglobulin G; D007130:Immunoglobulin Idiotypes; D014614:Vaccines, Synthetic